



KDCA

Korea Disease Control and Prevention Agency

Updates on COVID-19 in Republic of Korea

6 May 2021

COVID-19 vaccination status as of 0:00 today (cumulative since 26 February 2021)

	Total	City							
		Seoul	Busan	Daegu	Incheon	Gwangju	Daejeon	Ulsan	Sejong
New (1st dose)	5,253	1,788	287	726	6	40	10	24	245
New (1st dose)	25,310	1,650	1,764	1,104	1,827	654	0	0	238
Total (1st)	3,560,324	563,043	223,997	151,913	176,052	112,072	101,630	59,780	17,679
Total (2nd)	323,505	47,940	18,249	13,251	23,383	11,677	7,804	10,936	3,285
		Province							
		Gyeonggi	Gangwon	Chung-buk	Chung-nam	Jeon-buk	Jeon-nam	Gyeong-buk	Gyeong-nam
New (1st dose)	1,574	37	9	6	121	256	6	33	85
New (1st dose)	5,682	1,369	1,544	769	2,167	1,868	2,426	1,493	755
Total (1st)	779,301	142,378	132,515	175,184	182,700	212,655	230,167	255,522	43,736
Total (2nd)	54,506	18,420	18,563	15,055	19,402	17,694	15,335	19,481	8,524

※ Figures subject to correction recording update

Adverse events following COVID-19 vaccination reported as of 0:00 today (cumulative since 26 February 2021)

		Vaccinated (cumulative)	Total	%	General ¹⁾	Anaphylaxis suspected ²⁾	Severe suspected ³⁾	Deaths
Total	New	3,883,829	150	139	11	-	1	10
	Total		18,260		17,625	635	88	181
AstraZeneca	New	1,922,778	101	96	5	-	1	4
	Total		15,465		15,036	429	47	146
Pfizer	New	1,961,051	49	43	6	-	-	6
	Total		2,795		2,589	206	41	35

¹⁾ Mild cases such as headache, fever, nausea, vomiting, etc.

²⁾ Anaphylactoid reaction and anaphylactic shock suspected cases reported by healthcare institutions; Anaphylactoid reaction refers to occurrence of symptoms such as shortness of breath, rashes, etc. within 2 hours of vaccination and differs from anaphylaxis

³⁾ Includes convulsion and other nervous system response and ICU admitted cases

※ Based on the patient's condition at the time of initial report (general, anaphylaxis suspected, severe suspected, death)

※ Cases reported as suspected cases of AEFI; causal association not yet determined; investigation for assessment of causal association to take place for deaths or anaphylaxis cases



KDCA

Korea Disease Control and Prevention Agency

Updates on COVID-19 in Republic of Korea

6 May 2021

Confirmed cases by gender and age group

		New cases (%)	Total cases (%)	Incidence rate* (per 100,000)
Total		574 (100)	125,519 (100)	242.09
Sex	Male	295 (51.39)	62,542 (49.83)	241.82
	Female	279 (48.61)	62,977 (50.17)	242.36
Age	80 or above	14 (2.44)	5,436 (4.33)	286.22
	70-79	33 (5.75)	9,019 (7.19)	250.03
	60-69	71 (12.37)	19,270 (15.35)	303.74
	50-59	112 (19.51)	23,230 (18.51)	268.03
	40-49	104 (18.12)	18,658 (14.86)	222.40
	30-39	82 (14.29)	16,978 (13.53)	240.99
	20-29	86 (14.98)	18,671 (14.88)	274.31
	10-19	38 (6.62)	8,797 (7.01)	178.06
0-9	34 (5.92)	5,460 (4.35)	131.61	

* Total (cumulative) number of cases reported since January 2020 by sex and age / Population by sex and age (based on resident registration data of the Ministry of the Interior as of January 2020)

※ Figures subject to correction based on findings from epidemiological investigations

Deaths and severe/critical patients by gender and age group

		New deaths (%)	Total deaths (%)	Case fatality rate (%)	Severe/critical (%)
Total		4 (100)	1,851 (100)	1.47	172 (100)
Sex	Male	3 (75.00)	920 (49.70)	1.47	105 (61.05)
	Female	1 (25.00)	931 (50.30)	1.48	67 (38.95)
Age	80 or above	3 (75.00)	1,022 (55.21)	18.80	44 (25.58)
	70-79	1 (25.00)	527 (28.47)	5.84	66 (38.37)
	60-69	0 (0.00)	216 (11.67)	1.12	38 (22.09)
	50-59	0 (0.00)	62 (3.35)	0.27	13 (7.56)
	40-49	0 (0.00)	14 (0.76)	0.08	8 (4.65)
	30-39	0 (0.00)	7 (0.38)	0.04	3 (1.74)
	20-29	0 (0.00)	3 (0.16)	0.02	0 (0.63)
	10-19	0 (0.00)	0 (0.00)	0.00	0 (0.00)
0-9	0 (0.00)	0 (0.00)	0.00	0 (0.00)	

* Case fatality rate (CFR) (%) = Number of deaths / Number of confirmed cases x 100

※ Figures subject to correction based on findings from epidemiological investigations

AGE DISTRIBUTION OF SEVERE/CRITICAL CASES

	4.23.	4.24.	4.25.	4.26.	4.27.	4.28.	4.29.	4.30.	5.1	5.2.	5.3.	5.4.	5.5.	5.6.
Total	127	136	136	132	156	160	157	164	174	170	164	162	173	172

* Severe/Critical: COVID-19 patients in isolation being treated with high flow oxygen therapy, mechanical ventilator, ECMO (Extracorporeal Membrane Oxygenation), CRRT (Continuous Renal Replacement Therapy)